ABVC Biopharma Inc
NASDAQ:ABVC
ABVC Biopharma Inc
Pre-Tax Income
ABVC Biopharma Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Pre-Tax Income
-$10.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-63%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Pre-Tax Income
-$324.8m
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
1%
|
|
Incyte Corp
NASDAQ:INCY
|
Pre-Tax Income
$1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Karuna Therapeutics Inc
NASDAQ:KRTX
|
Pre-Tax Income
-$433m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
Moderna Inc
NASDAQ:MRNA
|
Pre-Tax Income
-$4.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
See Also
What is ABVC Biopharma Inc's Pre-Tax Income?
Pre-Tax Income
-10.7m
USD
Based on the financial report for Dec 31, 2023, ABVC Biopharma Inc's Pre-Tax Income amounts to -10.7m USD.
What is ABVC Biopharma Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-63%
Over the last year, the Pre-Tax Income growth was 31%.